|Ahead of print publication
Interleukin 6 and disease transformation in chronic myeloid leukemia: A Northeast Indian population study
Kavyanjali Sharma1, Usha Singh2, Madhukar Rai3, Jyoti Shukla1, Vineeta Gupta4, Gopeshwar Narayan5, Sandip Kumar1
1 Department of Pathology, Institute of Medical Sciences, Banaras Hindu University, Varanasi, Uttar Pradesh, India
2 UGC Advanced Immunodiagnostic Training and Research Centre, Institute of Medical Sciences, Banaras Hindu University, Varanasi, Uttar Pradesh, India
3 Department of Medicine, Institute of Medical Sciences, Banaras Hindu University, Varanasi, Uttar Pradesh, India
4 Department of Pediatrics, Sir Sundarlal Hospital, Banaras Hindu University, Varanasi, Uttar Pradesh, India
5 Department of Molecular and Human Genetics, Institute of Science, Banaras Hindu University, Varanasi, Uttar Pradesh, India
Department of Pathology, Institute of Medical Sciences, Banaras Hindu University, Varanasi - 221 005, Uttar Pradesh
Source of Support: None, Conflict of Interest: None
Background: Interleukin 6 (IL6) has been suggested to be a valuable prognostic marker in chronic myeloid leukemia (CML). IL6 is a pleiotropic cytokine and plays an important role in immune response, hematopoiesis, and acute phase response. IL6 is regarded as a prominent target for clinical interventions.
Objective: The aim of the present study was to investigate the serum levels of IL6 in CML to provide greater insight to their role in disease transformation in Indian patients.
Materials and Methods: A total of 50 CML cases and 10 acute lymphocytic leukemia (ALL) cases along with 20 healthy controls were included in the study between 2015 and 2016. About 4 mL blood samples were collected from all cases in plain vial and serum was separated. Levels of IL6 were determined in all cases by enzyme-linked immunosorbent assay.
Results: The study suggests that both ALL and CML are associated with significantly elevated serum IL6 level than the healthy control group. Mean levels of serum IL6 are 223.4 ± 53.403 pg/mL in CML, 71.020 ± 29.549 pg/mL in ALL, and 5.360 ± 0.467 pg/mL in healthy control group. Serum IL6 correlated with different phases of CML. Mean IL6 levels are 50.93 ± 29.37 pg/mL in chronic phase (CP), 69.02 ± 22.60 pg/mL in accelerated phase (AP), and 652.77 ± 124.62 pg/mL in blast crisis (BC) phase of CML. In compared to CP and AP, in BC, IL-6 is significantly elevated (P = 0.00 and 0.00, respectively); however, we did not find a significant difference in IL-6 serum levels between CP and AP (P = 0.703).
Conclusion: Study suggests that the detection of IL6 level in newly diagnosed patient can predict the severity of the disease. There might be association of level of IL6 with the disease transformation.
Keywords: Accelerated phase, acute lymphocytic leukemia, blast crisis, chronic phase, interleukin 6, tyrosine kinase inhibitors
|How to cite this URL:|
Sharma K, Singh U, Rai M, Shukla J, Gupta V, Narayan G, Kumar S. Interleukin 6 and disease transformation in chronic myeloid leukemia: A Northeast Indian population study. J Can Res Ther [Epub ahead of print] [cited 2020 Jan 25]. Available from: http://www.cancerjournal.net/preprintarticle.asp?id=244438